This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Genetic Susceptibility to Kidney Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2010 by Baylor College of Medicine.
Recruitment status was:  Recruiting
M.D. Anderson Cancer Center
Information provided by:
Baylor College of Medicine Identifier:
First received: February 26, 2009
Last updated: December 2, 2010
Last verified: December 2010
This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and eventually provide a means of identifying a subgroup of individuals who are most likely to develop RCC. Such individuals may then be targeted for intervention programs such as chemoprevention or dietary modification.

Renal Cell Carcinoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genetic Susceptibility to Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Baylor College of Medicine:

Biospecimen Retention:   Samples With DNA

We will utilize the blood collected to run several laboratory analyses that will assess DNA damage/repair, telomere length, telomerase activity, and other genetic instability as predictors of RCC risk. All information linking this unique identifier to the participant will be kept in a secure location under lock-and-key password protected.

In addition, RCC tumor and adjacent normal tissue samples may be obtained from the MDACC Institutional Tissue Bank (ITB) for cases only. The samples obtained will be left over from surgical procedures, so as to prevent any additional distress to the patient.

Estimated Enrollment: 1600
Study Start Date: July 2008
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients with newly diagnosed (diagnosed within the year of enrollment) with possible Renal Cell Carcinoma (RCC)

Inclusion Criteria:

  • Adult patients of any ethnicity or sex, who have a been diagnosed with possible Renal Cell Carcinoma within the past year.

Exclusion Criteria:

  • Must not have received chemotherapy, biological therapy or radiation therapy in the 6 months preceding enrollment will
  • Must not have had RCC, or metastatic RCC,
  • Must not have had a renal transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00854022

Contact: Carmen Bedford 713-798-2179

United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: XIFENG WU    713-745-2485   
Sub-Investigator: Richard E. Link, MD, PhD         
Sub-Investigator: Brian J. Miles, MD         
Sponsors and Collaborators
Baylor College of Medicine
M.D. Anderson Cancer Center
Principal Investigator: Seth P. Lerner, MD Baylor College of Medicine
  More Information

Responsible Party: Seth P. Lerner, MD, Baylor College of Medicine Identifier: NCT00854022     History of Changes
Other Study ID Numbers: H-17150
Study First Received: February 26, 2009
Last Updated: December 2, 2010

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Disease Susceptibility
Genetic Predisposition to Disease
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Disease Attributes
Pathologic Processes processed this record on September 21, 2017